- Home
- OPFI vs ALLO Comparison
OPFI vs ALLO Comparison
Compare OPFI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPFI | ALLO |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | 445 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.2M | 252.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | OPFI | ALLO |
|---|---|---|
| Price | $9.04 | $2.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $13.50 | $8.27 |
| AVG Volume (30 Days) | 371.3K | ★ 4.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,000.00 |
| Revenue This Year | $120.20 | N/A |
| Revenue Next Year | $10.97 | N/A |
| P/E Ratio | $67.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.54 | $0.86 |
| 52 Week High | $14.63 | $2.80 |
Technical Indicators
Market Signals| Indicator | OPFI | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 44.21 | 55.82 |
| Support Level | $8.93 | $1.01 |
| Resistance Level | $9.64 | $2.80 |
| Average True Range (ATR) | 0.32 | 0.20 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 38.83 | 50.49 |
Price Performance
Historical ComparisonAbout OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.